{"id":"a-phase-tirofiban-z-phase-simvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (minor and major)"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1201391","moleculeType":"Small molecule","molecularWeight":"436.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tirofiban blocks the final common pathway of platelet aggregation by inhibiting the glycoprotein IIb/IIIa receptor, preventing thrombotic events in acute coronary syndromes. Simvastatin reduces cholesterol synthesis and has pleiotropic anti-inflammatory and endothelial-protective effects. The combination targets both acute thrombotic risk and chronic atherosclerotic disease progression.","oneSentence":"This is a combination therapy pairing tirofiban (a platelet glycoprotein IIb/IIIa inhibitor) with simvastatin (an HMG-CoA reductase inhibitor/statin) to provide dual antiplatelet and lipid-lowering effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:26.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)"},{"name":"Secondary prevention of cardiovascular events in patients with hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT00251576","phase":"PHASE3","title":"Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1999-11-01","conditions":"Acute Coronary Syndrome","enrollment":4497}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"A-Phase: tirofiban; Z-Phase simvastatin","genericName":"A-Phase: tirofiban; Z-Phase simvastatin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination therapy pairing tirofiban (a platelet glycoprotein IIb/IIIa inhibitor) with simvastatin (an HMG-CoA reductase inhibitor/statin) to provide dual antiplatelet and lipid-lowering effects. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Secondary prevention of cardiovascular events in patients with hyperlipidemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}